SCHEMBL7674444

SCHEMBL7674444

Fc1cc(Cc2ccccn2)ccc1Br

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
NPC1 O15118 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
CACNA1B Q00975 3/20 0.41
HRH1 P35367 1/20 0.41
PARP1 P09874 1/20 0.40
ALDH1A1 P00352 1/20 0.39
S1PR1 P21453 2/20 0.39
HRH3 Q9Y5N1 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HRH4 Q9H3N8 1/20 0.37
TSHR P16473 1/20 0.37
LMNA P02545 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30063557 0.80 L3MBTL1 (0.51) L3MBTL1MAPTRAB9AHRH1ALDH1A1
SCHEMBL30062621 0.78 L3MBTL1 (0.47) L3MBTL1NPC1MAPTRAB9AHRH1
SCHEMBL7443189 0.77 L3MBTL1 (0.58) L3MBTL1NPC1CYP1A2CYP3A4MAPT
SCHEMBL7680189 0.77 L3MBTL1 (0.46) L3MBTL1MAPTHRH1ALDH1A1TSHR
SCHEMBL16922694 0.76 KDM1A (0.39) CYP1A2CYP3A4MAPTCYP2C9CYP2C19
SCHEMBL3233668 0.75 L3MBTL1 (0.65) L3MBTL1MAPTRAB9AHRH1HRH3
SCHEMBL31068243 0.75 L3MBTL1 (0.65) L3MBTL1NPC1MAPTRAB9AHRH1
SCHEMBL1043331 0.75 CALM1 (0.48) LMNA
SCHEMBL1773197 0.75 L3MBTL1 (0.65) L3MBTL1NPC1MAPTRAB9AHRH1
SCHEMBL31424381 0.75 KDM4E (0.50) CYP1A2CYP3A4MAPTCYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037888-A1 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease MERCK & CO., INC. 2002-03-28 US disclosed
US-6284755-B1 Inhibitors of prenyl-protein transferase MERCK & CO., INC. 2001-09-04 US disclosed
WO-2000034437-A2 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2000-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037888-A1 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease FNTA, PKD1, FNTB L3MBTL1 2951/4885NPC1 192/4885CYP1A2 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.